Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (641-650 of 709) with videos related to

Pageof 71
Sort By:
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trialRui-Hua Xu, Kei Muro, Satoshi Morita, et al.
Targeted Oncology|January 9, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal CancerYu Sunakawa, Yasutoshi Kuboki, Jun Watanabe, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|September 3, 2025
Aspirin-Free Prasugrel Monotherapy After Percutaneous Coronary Intervention in Patients With Non-ST Elevation Acute Coronary SyndromeKotaro Miyashita, Takashi Muramatsu, Pruthvi C Revaiah, et al.
Asiaintervention|March 20, 2023
Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot studyShinichiro Masuda, Takashi Muramatsu, Yuki Ishibashi, et al.
British Journal of Cancer|March 4, 2023
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trialYasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 11, 2022
Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinomaNaoto Fujita, Naoya Kanogawa, Hirokazu Makishima, et al.
International Cancer Conference Journal|April 3, 2026
Exploratory case series of conversion to carbon ion radiotherapy after systemic therapy in advanced hepatocellular carcinomaHaruka Anzai, Chihiro Miwa, Sadahisa Ogasawara, et al.
Circulation. Cardiovascular Interventions|July 8, 2026
Optical Coherence Tomography Characterization of Coronary Lithotripsy Following Atherectomy for Treatment of Severely Calcified LesionsYohei Sotomi, Nehiro Kuriyama, Yutaka Tanaka, et al.
Liver Cancer|March 27, 2025
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic TherapyMasanori Inoue, Sadahisa Ogasawara, Kazufumi Kobayashi, et al.
Cardiovascular and Interventional Radiology|May 30, 2024
Twenty-Four-Month Safety and Effectiveness of TCD-17187 Drug-Coated Balloon for Treatment of Atherosclerotic Lesions in Superficial Femoral and Proximal Popliteal ArteryYoshimitsu Soga, Osamu Iida, Shu-Ichi Seki, et al.
Pageof 71

Showing results (641-650 of 709) with videos related to

Sort By:
Pageof 71
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trialRui-Hua Xu, Kei Muro, Satoshi Morita, et al.
Targeted Oncology|January 9, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal CancerYu Sunakawa, Yasutoshi Kuboki, Jun Watanabe, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|September 3, 2025
Aspirin-Free Prasugrel Monotherapy After Percutaneous Coronary Intervention in Patients With Non-ST Elevation Acute Coronary SyndromeKotaro Miyashita, Takashi Muramatsu, Pruthvi C Revaiah, et al.
Asiaintervention|March 20, 2023
Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot studyShinichiro Masuda, Takashi Muramatsu, Yuki Ishibashi, et al.
British Journal of Cancer|March 4, 2023
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trialYasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 11, 2022
Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinomaNaoto Fujita, Naoya Kanogawa, Hirokazu Makishima, et al.
International Cancer Conference Journal|April 3, 2026
Exploratory case series of conversion to carbon ion radiotherapy after systemic therapy in advanced hepatocellular carcinomaHaruka Anzai, Chihiro Miwa, Sadahisa Ogasawara, et al.
Circulation. Cardiovascular Interventions|July 8, 2026
Optical Coherence Tomography Characterization of Coronary Lithotripsy Following Atherectomy for Treatment of Severely Calcified LesionsYohei Sotomi, Nehiro Kuriyama, Yutaka Tanaka, et al.
Liver Cancer|March 27, 2025
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic TherapyMasanori Inoue, Sadahisa Ogasawara, Kazufumi Kobayashi, et al.
Cardiovascular and Interventional Radiology|May 30, 2024
Twenty-Four-Month Safety and Effectiveness of TCD-17187 Drug-Coated Balloon for Treatment of Atherosclerotic Lesions in Superficial Femoral and Proximal Popliteal ArteryYoshimitsu Soga, Osamu Iida, Shu-Ichi Seki, et al.
Pageof 71